Press
releases

Bukwang said it registered patents on the use and composition of ‘JM-010’ with Korean Intellectual Property Office (Title : Combinations of serotonin receptor agonists for treatment of movement disorders). ‘JM-010’ is a treatment for ‘Levodopa-induced dyskinesia in Parkinson’s disease’ developed by Bukwang’s subsidiary named Contera Pharma ApS, which is a Danish bio venture specialized in […]

Bukwang recently announced that Ministry of Food and Drug Safety (MFDS) has granted JM-010 for the treatment of levodopa-induced dyskinesia (LID). JM-010 is currently being developed by a CNS specialized bioventure Contera Pharma, a subsidiary of Bukwang. LID is a movement disorder occurs inevitably in 60~70% of Parkinson’s disease patients who receive long-term levodopa treatment. […]

Bukwang Pharma and its fully owned subsidiary Contera Pharma are pleased to announce that the investigational medical product, JM-010 has successfully been dosed to cohorts of patients with Parkinson’s disease suffering from moderate to severe levodopa-induced dyskinesia in a Phase IIa/Proof-of-Concept study. The primary study objectives concerning efficacy and safety were fulfilled. The aim is […]

Bukwang Pharm and its fully owned subsidiary Contera Pharma are pleased to announce that the United State patent covering the investigational medical product, JM-010 and analogues thereof has been granted. Dr. Hee-Won Yoo, President and co-CEO of Bukwang Pharm stated: “The US patent is a significant milestone for Bukwang Pharm and supports the further development […]

Bukwang Pharma and its fully owned subsidiary Contera Pharma are pleased to announce that the investigational medical product, JM-010 has been dosed to the first patients with Parkinson’s disease suffering from moderate to severe levodopa-induced dyskinesia. The Phase IIa/Proof-of-Concept study is a randomized, double-blind, placebo-controlled, 2-way crossover study, which will assess the efficacy, safety/tolerability and […]

Solural Pharma and Contera Pharma have in collaboration with Ernst Moritz Arndt University Greifswald, Germany and Erweka GmbH, Germany been awarded a Eurostar grant to support a project to develop new treatments of morning akinesia associated with Parkinson’s disease (PD). Parkinson’s disease, which affects 1 in 100 people over the age of 60, is primarily […]